BioSpace News Archive

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced new regulatory designations for eltanexor.

Bristol Myers Squibb (NYSE:BMY) today announced, in collaboration with Disability Solutions, a U.S.- based non-profit organization that supports companies globally to achieve true disability inclusion, the launch of the Disability Diversity in Clinical Trials (DDiCT) initiative.

AIM ImmunoTech Inc. today reported follow-on data from its previously published single-center named patient program.

Arcaea announced the acquisition of Gadusol Laboratories, an early stage company using synthetic biology technology to produce the natural sun protective compounds found in marine life.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted marketing authorization by the European Commission.

Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) announces that it will release its financial results for the second quarter ended June 30, 2022, after the market closes on Monday, August 8, 2022.

GenSight Biologics reported that after 5 years of follow-up, Leber Hereditary Optical Neuropathy (LHON) subjects treated with LUMEVOQ® (GS010) continued to experience significantly improved vision as a result of a one-time injection of the gene therapy treatment. Compared to the trend in vision observed among untreated patients, the findings are a significant divergence from the natural outcomes of LHON.

Spexis AG a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET.

Biodesix, Inc. announced that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine Feinberg School of Medicine, Northwestern University will present the results of a retrospective analysis at the IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer on August 8, 2022 in Vienna, Austria.

Nanomerics Ltd., a private speciality pharmaceutical company, announced that the company’s Chief Scientific Officer, Professor Ijeoma F. Uchegbu, had been made an Honorary Fellowship of the UK’s Royal Society of Chemistry.